三类械成必答题？敷尔佳 贝泰妮 巨子生物布局医美注射赛道

This article breaks down the key details behind the wave of well-known skincare and medical dressing brands entering the medical aesthetic injectable market, with direct relevance to everyday consumer choices for aesthetic treatments and skincare products.

1. Top brands including Voolga, Botanee, and Giant Biogene are all launching their first Class III medical device-certified injectable products: Voolga’s "Blossom Kinetic Booster" will launch in October, formulated to improve dry, dull adult skin; Botanee’s self-developed "injectable sodium hyaluronate solution"—commonly known as a water-light injection—has just received Class III medical device approval; Giant Biogene’s "Collgene Core 753 Collagen Injection" has already officially launched.

2. The core drivers of this collective push into injectable aesthetics are twofold: the brands’ core medical dressing category has become mired in price wars that erode profit margins, and the implementation of the medical insurance personal account payment whitelist at the end of September will bar medical dressings from being covered by personal medical insurance accounts, creating significant revenue volatility in existing business lines and pushing brands to seek new growth drivers.

3. These newly launched injectables generally focus on improving the dermal extracellular matrix (ECM) microenvironment, an efficacy claim backed by authoritative academic research. When selecting relevant aesthetic treatments, consumers are advised to prioritize products with formal Class III medical device certification and avoid unapproved parallel imports or counterfeit products.

This article covers the industry trend of leading players in the efficacious skincare and medical dressing segments collectively entering the Class III medical device-certified medical aesthetic injectable market, providing clear reference value for brand business decision-making.

1. Category expansion trend reference: Brands that previously centered their medical device portfolios on Class II medical dressings are普遍 facing intensifying price wars and compressed margins in the dressing category. Compounded by the new medical insurance personal account payment whitelist regulation taking effect at the end of September 2026, which excludes dressing products from personal account payment channels and causing notable revenue volatility in related segments, the high-barrier Class III medical aesthetic injectable track has become the core direction to drive recovery in the medical device business.

2. Product R&D and marketing direction reference: New entrants in the injectable category are universally anchoring their value propositions on extracellular matrix (ECM) regulation. Both hyaluronic acid-based water-light injections and recombinant collagen injectables highlight their ability to replenish dermal support structures and improve skin condition, addressing core consumer pain points around anti-aging and skin quality improvement—a positioning also supported by academic research published in top-tier journals.

3. Track validation reference: Bloomage Biotech, which laid out early布局 in this space, saw its two water-light injection products record over 150% year-over-year sales growth in the first half of 2026; one SKU launched less than a year ago already generated nearly RMB 100 million in sales, validating the growth potential of this track.

This article releases critical business information including policy changes and incremental track opportunities in the medical aesthetic and efficacious skincare sectors, offering direct guidance for sellers to adjust product selection and mitigate risks.

1. Clear risk warning: Following the implementation of the medical insurance personal account payment whitelist system across regions at the end of September this year, medical dressing products marketed under Class I/II medical device registrations will no longer be eligible for payment via personal medical insurance accounts. Sales of dressing products that previously relied on medical insurance as a customer acquisition channel will see a significant impact, so sellers need to adjust inventory and sales strategies for this category in advance to avoid overstocking.

2. Clear opportunity indicator: Class III medical device-certified aesthetic injectables represent a high-growth track with strong certainty. Bloomage Biotech’s two water-light injection products saw unit sales grow over 150% year-over-year in the first half of 2026, with "Runzhiti Tou"—a SKU launched less than a year ago—approaching RMB 100 million in sales. The upcoming concentrated launch of first-ever Class III injectable products from Voolga, Botanee, and Giant Biogene represents a high-potential category worth prioritizing.

3. Demand shift reminder: Consumer demand for aesthetic injectables has evolved from basic filling to root-cause skin condition improvement. Products focused on dryness relief, dullness brightening, collagen regeneration, and ECM microenvironment regulation are more likely to win consumer recognition.

This article reveals shifting product demand and new business partnership opportunities in the medical aesthetic and medical dressing sectors, providing important reference for manufacturers to adjust their business布局.

1. Demand warning for traditional categories: Class II medical dressings have become a major battleground for price wars, compounded by tightening medical insurance payment policies. Profit margins for dressing orders from brand clients will continue to be compressed, so manufacturers should avoid over-reliance on production orders for this category and proactively explore new business directions.

2. Clear business opportunities: Multiple leading skincare and dressing brands including Voolga, Botanee, and Giant Biogene are collectively expanding into Class III medical aesthetic injectables, covering two major segments: hyaluronic acid water-light injections and recombinant collagen injectables. These products are positioned to improve dry, dull skin, replenish dermal collagen, and regulate the ECM microenvironment. Manufacturers with Class III medical device production qualifications should prioritize pursuing joint R&D and custom production partnerships with these brands.

3. Product design reference: Based on the performance of existing breakout products, injectables with clear skin improvement targets and backing from authoritative academic research are more likely to gain recognition from both brand partners and the broader market.

This article outlines the business布局 moves and existing operational pain points of leading players in the efficacious skincare and medical aesthetic sectors, providing reference for service providers to identify service directions and align with client needs.

1. Industry trend assessment: The traditional medical dressing track has reached peak growth, compounded by tightening medical insurance payment policies. Leading industry players are collectively shifting from the dressing category to the Class III medical aesthetic injectable track. Over the next two to three years, aesthetic injectables will become the core category for brands’ marketing investment and channel expansion.

2. Client pain point identification: Most brands entering the injectable track previously focused on mass-market skincare and Class II medical dressings, lacking experience in professional clinic channel distribution, compliant marketing communications, and clinician education for Class III medical aesthetic products. They also need to build efficacy communication frameworks for new products that are supported by professional academic evidence.

3. Service direction reference: There will be clear market demand for services supporting Class III injectable products, including compliant marketing, clinic channel matchmaking, and academic content development. Drawing on Bloomage Biotech’s breakout product playbook, service providers capable of helping new brands rapidly build blockbuster SKUs will be particularly favored by brand clients.

This article reflects category trends and merchant movements in the medical aesthetic and efficacious skincare sectors, providing reference for platforms to adjust merchant recruitment, category operation, and compliance risk control strategies.

1. Merchant recruitment adjustment reference: Medical dressing products have shown slowing growth due to fierce price wars and medical insurance payment restrictions. Platforms can prioritize onboarding brand merchants offering Class III medical aesthetic injectables, including leading players such as Voolga, Botanee, and Giant Biogene which are poised to launch new products, to capture category growth dividends. For context, comparable products from Bloomage Biotech delivered 150% half-year sales growth, with a new SKU reaching nearly RMB 100 million in sales within its first year, demonstrating that this category can deliver clear incremental revenue for platforms.

2. Category operation direction reference: Platforms can focus on building consumer mindshare around aesthetic injectables positioned for root-cause ECM improvement, dry and dull skin repair, and collagen regeneration, to align with consumer demand for upgraded aesthetic services.

3. Compliance risk control reminder: Platforms must strictly verify the Class III medical device qualifications of aesthetic injectable products to prevent unqualified, non-compliant products from being listed. For medical dressing products, platforms should also update advertising rules in a timely manner to prohibit merchants from implying products are eligible for medical insurance payment, mitigating compliance risks.

This article documents new industrial developments in China’s efficacious skincare and medical device sectors in 2026, providing a real-world industry sample for related industrial research and trend analysis.

1. Core new industrial trend: Three leading enterprises previously focused on Class II medical dressings and efficacious skincare—Voolga, Botanee, and Giant Biogene—are all launching their first Class III medical aesthetic injectable products in 2026, formally entering the aesthetic injectable track. This shift reflects a collective move by efficacious skincare firms to expand into the high-barrier medical aesthetic end-market as growth in the medical dressing segment peaks.

2. Drivers of industrial change: First, the medical dressing category has fallen into price wars that continue to compress margins, with notable revenue volatility in the medical device segments of relevant firms over the past three years; Voolga and Botanee saw their medical device revenue nearly halved in the first half of 2025. Second, new medical insurance regulations issued in May 2026, requiring implementation of the personal account payment whitelist by the end of September, cut off personal account payment channels for dressing products, forcing enterprise transformation. Third, the Class III aesthetic injectable track offers strong growth certainty, as evidenced by Bloomage Biotech’s comparable products recording over 150% year-over-year sales growth in the first half of 2026, validating the viability of the business model.

3. New R&D trend: New entrants in the injectable segment are universally anchoring their technology roadmaps on extracellular matrix (ECM) regulation, with stronger emphasis on academic evidence backing product efficacy.